Tempus acquires Personalis for ~$1.5B
Tempus is acquiring molecular-residual-disease testing company Personalis for roughly $1.5B, folding MRD testing into its precision-oncology platform.
Business Wire and Fierce Biotech (2026-07-20) reported Tempus’s acquisition of Personalis, its cancer-genomics partner, in a deal valued around $1.5B. The stated rationale is integrating minimal/molecular residual disease (MRD) testing more tightly into the AI-enabled precision oncology platform.
Diagnostics pricing is reimbursement-driven rather than list-priced, so no immediate change to the published commercial terms is expected. Logged for the About/positioning section.
Tempus agreed to acquire molecular-residual-disease (MRD) testing company Personalis for roughly $1.5B, folding MRD more tightly into its precision-oncology platform. As with Ambry and Paige, it is an M&A-as-moat move — deepening the licensable multimodal dataset and MRD menu (alongside Tempus's own xM) rather than changing a posted price; diagnostics pricing stays reimbursement-driven, so no immediate change to commercial terms was announced.